WO2022022226A1 - 一种具有抗衰老活性的多肽及其应用 - Google Patents

一种具有抗衰老活性的多肽及其应用 Download PDF

Info

Publication number
WO2022022226A1
WO2022022226A1 PCT/CN2021/104283 CN2021104283W WO2022022226A1 WO 2022022226 A1 WO2022022226 A1 WO 2022022226A1 CN 2021104283 W CN2021104283 W CN 2021104283W WO 2022022226 A1 WO2022022226 A1 WO 2022022226A1
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptide
aging
elegans
nematodes
thr
Prior art date
Application number
PCT/CN2021/104283
Other languages
English (en)
French (fr)
Inventor
让•马丁内斯
徐寒梅
王栋
Original Assignee
南京安吉生物科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 南京安吉生物科技有限公司 filed Critical 南京安吉生物科技有限公司
Priority to US17/767,403 priority Critical patent/US20240067676A1/en
Priority to EP21849796.4A priority patent/EP4190796A1/en
Priority to AU2021314719A priority patent/AU2021314719A1/en
Priority to JP2022521564A priority patent/JP2022551893A/ja
Publication of WO2022022226A1 publication Critical patent/WO2022022226A1/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0216—Solid or semisolid forms
    • A61K8/022—Powders; Compacted Powders
    • A61K8/0225—Granulated powders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/84—Products or compounds obtained by lyophilisation, freeze-drying
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/92—Oral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • Aging is a process in which the body goes through a period of sexual maturity, the self-renewal and repair capabilities of cells are weakened, the structure and function of tissues and organs degenerate, and eventually die. Risk increases. With the aging of the global population, various degenerative diseases of the elderly and the huge medical expenses incurred have become more and more serious social problems. Maintaining the healthy state of the elderly population is a key link in reducing the social and economic burden brought about by population aging. Therefore, it is of great significance to explore measures and methods for intervening in aging and aging-related diseases that are simple, economical, effective, safe and suitable for promotion.
  • C. elegans As a classic model animal for studying aging, C. elegans has the following advantages: firstly, its relatively short lifespan, only 2-3 weeks under standard laboratory conditions, makes lifespan survival analysis possible; secondly, in controlled It is easy to obtain a large number of genetically identical animals under environmental conditions; third, the transparency of the worm body facilitates the direct observation of how cells and tissues change with age; Research to aid in anti-aging.
  • a major advantage of the C. elegans model is the ease with which genetic methods can be used to provide biological information, allowing the identification of a large number of genetic mutations that can alter lifespan.
  • C. elegans lifespan exhibits remarkable plasticity and may be affected by environmental, nutritional, and genetic mutations, and even under controlled conditions, individual lifespan may vary, revealing stochastic factors in aging. Therefore, C. elegans can be used as a model animal to study the anti-aging activity of drugs.
  • anti-aging drugs By far the most common form of anti-aging is the use of anti-aging drugs.
  • Most of the anti-aging drugs used clinically are synthetic drugs, such as vitamin E, which can promote cell division and inhibit the generation of oxygen free radicals, procaine preparations can prolong cell lifespan, and amidopyrone can delay brain aging, etc.
  • Oxidative stress delaying the decline of body function caused by aging, thereby prolonging the lifespan of nematodes
  • Metformin as an activator of adenylate-activated protein kinase (AMPK)
  • AMPK adenylate-activated protein kinase
  • PAL-12 A six-membered peptide
  • resveratrol analogs and other drugs are also favored for their anti-aging effects.
  • the polypeptide is characterized in that X is T or A.
  • the polypeptide can enhance the motor behavior ability of C. elegans, improve the pressure stress ability, improve the decline of the exercise ability in the aging process, and prolong the average lifespan.
  • one or more pharmaceutically acceptable adjuvants can also be added to the above-mentioned medicines, and the adjuvants include conventional diluents, fillers, adhesives, wetting agents, absorption enhancers, surface active agents in the pharmaceutical field. agents, lubricants and stabilizers.
  • the medicine of the present invention can be made into various forms such as injection, freeze-dried powder injection, tablet or granule.
  • the medicines in the above-mentioned various dosage forms can be prepared according to the conventional methods in the pharmaceutical field.
  • the polypeptide of the present invention has a novel structure, the basic unit of which is composed of natural amino acids, and is easy to synthesize, separate and purify;
  • the polypeptide of the present invention has good safety, weak adverse reactions and toxic side effects, does not affect the growth and development of Caenorhabditis elegans, and does not affect the reproductive ability of the nematodes;
  • the anti-aging effect of the polypeptide involved in the invention has good performance in the Caenorhabditis elegans model, and is specifically embodied in significantly improving the motor behavior of the nematode, delaying the decline of the motor ability in the aging process of the nematode, prolonging half of the survival days of the nematode, and increasing the pressure of the nematode Stress capacity, extending the lifespan of nematodes.
  • Figure 2 Results of the effect of polypeptides on the body length and width of Caenorhabditis elegans. Among them, picture A is the result of body length, and picture B is the result of body width. The results are expressed as Mean ⁇ SEM. Compared with the blank group, n.s. means no significant difference, *P ⁇ 0.05 means significant difference, **P ⁇ 0.01 means very significant difference. There was no significant difference between the polypeptide group and the blank group, indicating that the polypeptides Ace and RV1 did not affect the normal growth and development of C. elegans, and the polypeptides had good safety.
  • Figure 3 Results of the effect of polypeptides on the number of broods in Caenorhabditis elegans. The results are expressed as Mean ⁇ SEM. Compared with the blank group, n.s. means no significant difference, *P ⁇ 0.05 means significant difference, **P ⁇ 0.01 means very significant difference. There was no significant difference between the polypeptide group and the blank group, indicating that the polypeptides Ace and RV1 did not affect the normal reproductive ability of C. elegans, and the polypeptide had good safety.
  • Figure 4 Results of the effect of polypeptides on the motor behavior of Caenorhabditis elegans.
  • picture A is the result of head swing
  • picture B is the result of body bending
  • picture C is the result of pharyngeal pump frequency.
  • the results are expressed as Mean ⁇ SEM.
  • n.s. means no significant difference
  • *P ⁇ 0.05 means significant difference
  • **P ⁇ 0.01 means very significant difference.
  • the polypeptide group had significant differences, indicating that both polypeptides Ace and RV1 could enhance the muscle movement of C. elegans and improve the locomotor behavior of C. elegans.
  • FIG. 5 Survival curves of acute heat stress experiments in C. elegans. Picture A is the survival curve of Day4 acute heat stress experimental nematodes, and picture B is the survival curve of Day8 acute heat stress experimental nematodes. It can be seen from the figure that both Ace and RV1 peptide groups can significantly improve the ability of nematodes to acute heat stress, indicating that the peptide drug can prolong the life cycle of nematodes in a thermal environment.
  • Fig. 7 The detection results of the acute oxidative stress experiment of Caenorhabditis elegans. Picture A is the detection result of the acute oxidative stress test on Day4, and picture B is the detection result of the acute oxidative stress test on Day8. The results are expressed as Mean ⁇ SEM. Compared with the blank group, *P ⁇ 0.05 is a significant difference, and **P ⁇ 0.01 is a very significant difference. It can be seen from the figure that the survival rate of nematodes in the Ace and RV1 polypeptide groups is significantly higher than that in the blank group, which indicates that the polypeptide drug can prolong the life cycle of nematodes in an oxidative environment.
  • Figure 8 Motility rating results of acute oxidative stress experiments in C. elegans.
  • picture A shows the exercise rating results of the nematodes in the acute oxidative stress experiment on Day 4
  • picture B shows the exercise ability grading results in the nematodes in the acute oxidative stress experiment on Day 8.
  • the proportion of nematodes in the Ace and RV1 polypeptide groups in the A-level group is higher than that of the blank group, which further indicates that the polypeptide drug can enhance the ability of C. elegans acute oxidative stress;
  • the Day4 acute oxidative stress experiment there was no difference in exercise between the peptide group and the blank group.
  • Figure 9 Results of motility rating of C. elegans at different ages.
  • picture A is the grading result of the nematode motility at the time point of Day4
  • picture B is the grading result of the movement ability of the nematodes at the time point of Day8
  • picture C is the grading result of the movement ability of the nematodes at the time point of Day12.
  • Ace and RV1 peptide groups at Day8 and Day12 had a significantly higher proportion of nematodes in grade A than the blank group, which means that the peptides can delay the muscle aging of C. elegans. Increases the mobility of the nematode, thereby extending the lifespan of the nematode.
  • Figure 10 The results of motility testing of C. elegans at different ages. Among them, picture A is the test result of nematode motility at the time point of Day4, picture B is the test result of the movement ability of nematodes at the time point of Day8, and picture C is the test result of the movement ability of nematodes at the time point of Day12. The results are expressed as Mean ⁇ SEM. Compared with the blank group, *P ⁇ 0.05 is a significant difference, and **P ⁇ 0.01 is a very significant difference.
  • the Ace and RV1 peptide groups had significantly higher head swings than the blank group, and the frequency of pharyngeal pump at Day 12 was also significantly higher than that of the blank group, which means that the peptide can delay
  • the muscle aging of C. elegans increases the motor behavior of the nematode, delays the decline of the nematode's mobility, and thus prolongs the lifespan of the nematode.
  • Escherichia coli OP50 culture conditions: shaking incubator, 220rpm, 37°C
  • RV1 AKFAA, 10 nM
  • Synchronization of Caenorhabditis elegans Select an NGM petri dish with a moderate nematode density, pick L4 larvae with a picking needle, transfer them to a blank NGM petri dish, pick about 20 larvae in total, and wait until they develop into adults and give birth After the first batch of eggs, all the adults were picked away. After about 12 hours, the eggs hatched into larvae, and the synchronized L1-stage larvae were obtained.
  • Preliminary preparation for the C. elegans lifespan experiment Rinse the NGM medium with 1 ml of M9 buffer, collect the buffer containing the L1 stage larvae in an EP tube, place in a chromatographic cabinet at 4°C for 5 minutes, centrifuge at 1500xg/4°C for 3 minutes, and discard After the supernatant was resuspended in 100 ⁇ l buffer, the nematodes were counted under the microscope, and then the nematode concentration was diluted to 30 worms/10 ⁇ l; the NGM culture dish inoculated with E. , to ensure that the number of nematodes is about 30, and then place the NGM petri dish in a constant temperature incubator for cultivation.
  • Caenorhabditis elegans lifespan experiment After the L1 stage nematodes developed to the L4 stage, 100 ⁇ l of 15.6 ⁇ g/ml 5-FUDR was added to inhibit the oviposition of C. elegans; when the nematodes developed into adults, the drug was started and divided into control groups , 10nM administration group, this time was recorded as the first day of the lifespan experiment; after that, daily administration, observed and recorded the number of nematodes that survived, died and unexpectedly died, and observed and recorded the state of nematodes until the last nematode died. The criteria for judging death are: C.
  • Reproductive ability detection of Caenorhabditis elegans Collect the larvae at L1 stage after synchronization, spread them on NGM solid medium inoculated with Escherichia coli OP50, and divide them into Control group and 10nM administration group, which are placed in a constant temperature and humidity incubator Cultured to L4 stage larvae.
  • Detection of motor behavior of C. elegans larvae at L1 stage after synchronization were plated on NGM solid medium inoculated with Escherichia coli OP50, divided into Control group and 10nM administration group, placed in a constant temperature and humidity incubator Culture for 48h. Then, the following three indicators of motor behavior were detected: head swing frequency, 20 nematodes were picked from each group to a new clean medium, and after 1 hour of adaptation and recovery, an appropriate amount of M9 buffer was added and observed under an inverted microscope.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

提供了一种能够延长秀丽隐杆线虫寿命的多肽，该多肽具有氨基酸序列XKFAA(X：任意氨基酸，优选为T/A)或其药学上可以接受的盐，或在上述序列基础上，进行一个或多个氨基酸被删除、置换或添加后仍具有抗衰老活性的多肽或其药学上可以接受的盐。该多肽具有延长秀丽线虫寿命，抵抗衰老的作用，同时具有增强运动行为能力，提高压力应激能力和改善衰老进程中运动能力衰退的作用。

Description

一种具有抗衰老活性的多肽及其应用 技术领域
本发明属于生物药物领域，更具体地说，涉及一种具有抗衰老活性的多肽及其应用。
背景技术
衰老是机体在经过性成熟时期后，细胞的自我更新和修复能力减弱，组织器官的结构和功能退化，并最终走向死亡的过程，其特征表现在压力应激能力减退，平衡状态打破和罹患疾病风险增加。随着全球人口老龄化，多种老年退行性疾病以及随之产生的巨大的医疗费用已成为越来越严重的社会问题。保持老年人群健康状态是减轻人口老龄化带来的社会负担和经济负担的关键环节。因此，探索简便易行，经济有效，安全性高并适宜推广的干预衰老及衰老相关疾病的措施和方法意义重大。
在早期的衰老研究中，科学家认为纯粹的衰老研究应与衰老相关疾病严格区分开来。衰老相关疾病一般指伴随衰老其发病率增加的疾病。目前认为的衰老相关疾病主要为心血管疾病、肿瘤、风湿、骨质疏松、白内障、二型糖尿病、高血压及老年痴呆等。但随着衰老研究的推进，人们发现多种衰老相关疾病的发生发展与衰老进程具有同源性，衰老进程本身是众多衰老相关疾病的基本风险因子。社会责任也促使生物学家意识到，单独的延长寿命并不能减轻老龄化所带来的沉重的社会经济负担，只有延长健康寿命才具有现实意义。因此，如何降低衰老相关疾病，提高老年人晚年生存质量，延长健康寿命成为衰老研究的热点所在。目前，健康寿命并无严格的指标衡量，一般认为衰老干预手段能够在延长寿命的同时，提高机体的应激能力，降低衰老相关疾病的发生发展，改善衰老相关性退化，就可称为延长健康寿命。
秀丽隐杆线虫作为研究衰老的经典模式动物，其具有如下优势：首先，寿命相对较短，在标准实验室条件下仅2-3周，使整个寿命存活分析成为可能；其次，在受控的环境条件下容易获得大量遗传上相同的动物；第三，虫体透明方便直接观察细胞和组织是如何随年龄变化的；第四，对线虫的细胞组织，神经元连接和全基因组的深入了解有助于抗衰老的研究。秀丽线虫模型的一个主要优点是可以很容易地利用遗传方法来提供生物学信息，从而确定了大量可以改变寿命的基因突变。最后，秀丽线虫的寿命表现出显著的可塑性，并且可能受到环境条件、营养条件以及基因突变的影响，即使是在受控条件下，个体寿命也可能发生变化，从而揭示衰老的随机因素。因此，秀丽隐杆线虫可以作为研究药物抗衰老活性的模型动物。
目前为止，最普遍的抗衰老方式是使用抗衰老药物。临床上使用的延缓衰老的药物大多 是合成类药物，如维生素E可促进细胞分裂及抑制氧自由基生成、普鲁卡因制剂能延长细胞寿命、酰胺吡酮可延缓脑衰老等；阿司匹林通过对抗氧化应激，延缓衰老引起的机体功能下降，从而延长线虫寿命；二甲双胍作为腺苷酸活化蛋白激酶(AMPK)激活剂，也可改善认知障碍，对延缓衰老也有一定的作用；PAL-12(一个六元肽)、白藜芦醇类似物等药物的抗衰老作用也备受青睐。
发明内容
1.要解决的问题
本发明提供一种具有抗衰老活性的多肽及其应用，本发明的多肽能有效地延长秀丽隐杆线虫的寿命，具有良好的抗衰老效果并具有很大的开发前景。
2.技术方案
为了解决上述问题，本发明所采用的技术方案如下：
一种多肽，其特征在于：具有氨基酸序列XKFAA或其药学上可以接受的盐；X＝H-Pro-Pro-Thr-Thr-、H-Pro-Thr-Thr-、H-Thr-Thr-、或任意L/D构型氨基酸，或酰基，如乙酰基、丙酰基。
所述的一种多肽，其特征在于X为T或者A。
所述的多肽的氨基酸序列为TKFAA(命名为Ace)或AKFAA(命名为RV1)。
所述的多肽在制备抗衰老和/或延长寿命的药物或保健品中的应用。
所述多肽能够增强秀丽线虫的运动行为能力，提高压力应激能力和改善衰老进程中运动能力的衰退，延长平均寿命。
需要的时候，在上述药物中还可以加入一种或多种药学上可接受的辅料，所述辅料包括药学领域常规的稀释剂、填充剂、粘合剂、湿润剂、吸收促进剂、表面活性剂、润滑剂和稳定剂等。
本发明的药物可以制成注射液、冻干粉针剂、片剂或颗粒剂等多种形式。上述各种剂型的药物均可以按照药学领域的常规方法制备。
3.有益效果
相比于现有技术，本发明的有益效果为：
(1)本发明的多肽结构新颖，组成基本单位均为天然氨基酸，容易合成、分离和纯化；
(2)能够有效延长秀丽隐杆线虫的寿命，具有抗衰老的活性；
(3)本发明的多肽安全性好，不良反应和毒副反应弱，不影响秀丽隐杆线虫的生长发育，不影响线虫的生殖能力；
本发明涉及的多肽抗衰老效果在秀丽隐杆线虫模型中表现良好，具体表现在显著提高线 虫的运动行为能力，延缓线虫衰老进程中运动能力的衰退，延长线虫的半数生存天数，提高线虫的压力应激能力，延长线虫的寿命。
附图说明
图1多肽对秀丽隐杆线虫寿命影响实验的生存曲线。图中可以看出，Ace和RV1多肽组均具有延长秀丽线虫寿命的效果。
图2多肽对秀丽隐杆线虫体长体宽的影响结果。其中，A图为体长结果，B图为体宽结果。结果以Mean±SEM表示，与空白组对比，n.s.为没有显著性差异，*P<0.05为显著性差异，**P<0.01为非常显著性差异。多肽组与空白组相比没有显著性差异，说明多肽Ace和RV1不影响秀丽线虫正常的生长发育，该多肽具有良好的安全性。
图3多肽对秀丽隐杆线虫育雏数的影响结果。结果以Mean±SEM表示，与空白组对比，n.s.为没有显著性差异，*P<0.05为显著性差异，**P<0.01为非常显著性差异。多肽组与空白组相比没有显著性差异，说明多肽Ace和RV1不影响秀丽线虫正常的生殖能力，该多肽具有良好的安全性。
图4多肽对秀丽隐杆线虫运动行为能力的影响结果。其中，A图为头部摆动结果，B图为身体弯曲结果，C图为咽泵频率结果。结果以Mean±SEM表示，与空白组对比，n.s.为没有显著性差异，*P<0.05为显著性差异，**P<0.01为非常显著性差异。多肽组与空白组相比具有显著性差异，说明多肽Ace和RV1均能够增强秀丽线虫的肌肉运动，提高线虫的运动行为能力。
图5秀丽隐杆线虫的急性热应激实验的生存曲线。其中A图为Day4急性热应激实验线虫的生存曲线，B图为Day8急性热应激实验线虫的生存曲线。图中可以看出，Ace和RV1多肽组均能显著提高线虫急性热压力应激的能力，说明该多肽药物能够延长线虫在热环境下的生命周期。
图6秀丽隐杆线虫的急性热应激实验的运动力评级结果。其中A图为Day4急性热应激实验线虫的运动力评级结果，B图为Day8急性热应激实验线虫的运动力评级结果。图中可以看出Ace和RV1多肽组中A等级的线虫占比要高于空白组，这进一步说明该多肽药物能够增强秀丽线虫急性热应激的能力，即在热环境下的运动行为能力。
图7秀丽隐杆线虫的急性氧化应激实验的检测结果。其中A图为Day4急性氧化应激实验的检测结果，B图为Day8急性氧化应激实验的检测结果。结果以Mean±SEM表示，与空白组对比，*P<0.05为显著性差异，**P<0.01为非常显著性差异。图中可以看出，Ace和RV1多肽组线虫的存活率显著高于空白组，这说明该多肽药物能够延长线虫在氧化环境下的生命周期。
图8秀丽隐杆线虫的急性氧化应激实验的运动力评级结果。其中A图为Day4急性氧化应激实验线虫的运动力评级结果，B图为Day8急性氧化应激实验线虫的运动力评级结果。图中可以看出Day8时期急性氧化应激实验中，Ace和RV1多肽组中处于A等级的线虫占比要高于空白组，这进一步说明该多肽药物能够增强秀丽线虫急性氧化应激的能力；Day4急性氧化应激实验中，多肽组和空白组没有运动力上的差异性。
图9不同年龄段的秀丽线虫的运动能力评级结果。其中A图为Day4时间点对线虫运动能力评级结果，B图为Day8时间点对线虫运动能力评级结果，C图为Day12时间点对线虫运动能力评级结果。图中可以看出，Day8和Day12时间点Ace和RV1多肽组与空白组相比，处于A等级的线虫占比要明显高于空白组，这意味着，该多肽能够延缓秀丽线虫的肌肉衰老，增加线虫的行动能力，从而延长线虫的寿命。
图10不同年龄段的秀丽线虫的运动能力检测结果。其中A图为Day4时间点对线虫运动能力检测结果，B图为Day8时间点对线虫运动能力检测结果，C图为Day12时间点对线虫运动能力检测结果。结果以Mean±SEM表示，与空白组对比，*P<0.05为显著性差异，**P<0.01为非常显著性差异。图中可以看出，Ace和RV1多肽组与空白组相比，头部摆动次数显著高于空白组，且在Day12时间点咽泵频率也显著高于空白组，这意味着，该多肽能够延缓秀丽线虫的肌肉衰老，增加线虫的运动行为能力，延缓线虫行动力的衰退，从而延长线虫的寿命。
具体实施方式
下面结合具体实施例对本发明进一步进行描述。以下所述，仅是本发明的较佳实施例而已，并非对本发明做其他形式的限制，任何熟悉本专业的技术人员均可能利用以下揭示的技术内容加以变更为同等变化的等效实施例。凡是未脱离本发明方案内容，依据本发明的技术实质对以下实施例所做的任何简单修饰或等同变化，均落在本发明的保护范围内。
多肽Ace：TKFAA和多肽RV1：AKFAA由江苏省合成多肽药物发现与评价工程中心合成，纯度分别为96.30％，98.22％。
实施例1
多肽对秀丽隐杆线虫模型的寿命影响实验
1.实验材料
大肠杆菌OP50，培养条件：振荡培养箱，220rpm，37℃培养
野生型秀丽隐杆线虫，培养条件：恒温恒湿培养箱，20℃，湿度45％-55％
5-FUDR：15.6μg/ml
NaN 3：0.4M
H 2O 2：30mM
Ace：TKFAA，10nM
RV1：AKFAA，10nM
WD1：PPTTKFAA，10nM
WD2：PTTKFAA，10nM
WD3：TTKFAA，10nM
2.实验方法
秀丽隐杆线虫的同步化：选取线虫密度适中的NGM培养皿，用挑针挑取L4期的幼虫，转移到空白的NGM培养皿，一共挑取20只左右，待它们发育到成虫并且产下第一批卵后，将成虫全部挑走，大约12h后，卵孵化成幼虫，即可得到同步化后的L1期幼虫。
秀丽隐杆线虫寿命实验的前期准备：用1ml M9缓冲液冲洗NGM培养基，收集含有L1期幼虫的缓冲液于EP管中，4℃层析柜放置5min，1500xg/4℃离心3min，弃掉上清，100μl缓冲液重悬混匀后，于显微镜下计数线虫，然后稀释线虫浓度为30worms/10μl；取已接种大肠杆菌OP50的NGM培养皿，加入10μl的线虫稀释液，最后显微镜下观察计数，保证线虫数目在30只左右，然后将NGM培养皿置于恒温培养箱中培养。
秀丽隐杆线虫寿命实验：待L1期线虫发育到L4期，加入100μl的15.6μg/ml的5-FUDR，用来抑制秀丽线虫产卵；待线虫发育为成虫，开始给药，分为control组，10nM给药组，此时记为寿命实验的第1天；此后每天给药，每天观察记录存活、死亡和意外死亡的线虫数，观察记录线虫状态，直到最后一只线虫死亡。判断死亡的标准是：秀丽线虫对强光或敲击平板没有反应，高倍镜下咽部肌肉没有运动，最后用挑虫针敲击线虫的头部，若依然没有反应即可判断为死亡。死亡的线虫需要挑出培养皿，大肠杆菌OP50耗尽时及时添加。对数据进行Kaplan-Meier统计分析，数据结果以Median±SE表示，与Control组对比，*P<0.05为显著性差异，**P<0.01为非常显著性差异。
3.实验结果
(1)秀丽隐杆线虫寿命实验结果记录：
表1 秀丽隐杆线虫的剩余数的记录结果
Figure PCTCN2021104283-appb-000001
Figure PCTCN2021104283-appb-000002
Ace多肽组的死亡出现天数和空白组相比要相对推迟，且线虫的最长寿命为37天，比空白组多9天；RV1组的死亡出现天数和空白组相比没有明显差别，而线虫的最长寿命为36天，比空白组多8天；WD1、WD2和WD3组的死亡出现天数和空白组相比也没有明显差别，线虫的最长寿命为31天、32天和33天，比空白组多3天、4天和5天。详见表1和图1。
(2)秀丽隐杆线虫的半数死亡天数：
表2 秀丽隐杆线虫的半数死亡天数的检测结果
Figure PCTCN2021104283-appb-000003
注：以上结果用Median±SE表示；与Control组比，*P<0.05，**P<0.01
Ace给药组的半数死亡天数与空白组相比，具有显著性差异，说明Ace多肽具有延长秀丽线虫寿命的作用，能够延长寿命4天；RV1多肽的半数死亡天数与空白组相比，没有显著性差异，但其半数死亡天数要比空白组多2天；WD1、WD2和WD3组的半数死亡天数与空 白组相比，没有显著性差异，它们的半数死亡天数要比空白组多1天。相比之下，Ace和RV1多肽组的效果要好一些，因此，后续针对Ace和RV1两条多肽进行抗衰老评价实验。详见表2和图1，实验结果具有统计学意义。
实施例2
多肽对秀丽隐杆线虫的生长发育影响实验
1.实验材料
同实施例1。
2.实验方法
秀丽隐杆线虫的同步化：同实施例1。
秀丽隐杆线虫的生长发育实验：收集同步化至L1期的幼虫，铺在已接种大肠杆菌OP50的NGM固态培养基上，分为Control组，10nM给药组，置于恒温恒湿培养箱中进行培养72h，检测线虫成虫时期的体长和体宽，检测方法如下：每组分别挑取秀丽隐杆线虫20只，挑至新的NGM固态培养基上，然后滴加50μl的NaN 3，浓度为0.4M，待大部分虫体僵直后，于倒置显微镜下拍照记录，然后用Photoshop的标尺工具，即可测量秀丽线虫的体长和体宽。对数据进行One-way ANOVAY统计分析，数据结果以Mean±SEM表示，与Control组对比，*P<0.05为显著性差异，**P<0.01为非常显著性差异。
3.实验结果
表3 多肽对秀丽隐杆线虫的体长体宽的影响
Figure PCTCN2021104283-appb-000004
注：以上结果用Mean±SEM表示；与Control组比，*P<0.05，**P<0.01
多肽组与空白组相比，秀丽线虫的体长和体宽均没有显著性差异，这意味着，Ace和RV1多肽均不影响秀丽隐杆线虫正常的生长发育，说明此多肽具有良好的安全性。详见表3和图2，实验结果具有统计学意义。
实施例3
多肽对秀丽隐杆线虫的生殖能力影响实验
1.实验材料
同实施例1。
2.实验方法
秀丽隐杆线虫同步化：同实施例1。
秀丽隐杆线虫的生殖能力检测：收集同步化后L1期的幼虫，铺在已接种大肠杆菌OP50的NGM固态培养基上，分为Control组，10nM给药组，置于恒温恒湿培养箱中培养至L4期幼虫。每组分别挑取1只L4期幼虫于新的NGM固态培养基上，并保证在该线虫的产卵期内，每天将线虫转移到新的培养基上，含有虫卵的培养基继续在培养箱中培养24h，然后对每个平板上的幼虫进行计数相加，直到该线虫的产卵结束，相加后的数据即该线虫的子代总数目。每组重复记录10只线虫的子代数目。对数据进行One-way ANOVAY统计分析，数据结果以Mean±SEM表示，与Control组对比，*P<0.05为显著性差异，**P<0.01为非常显著性差异。
3.实验结果
表4 多肽对秀丽隐杆线虫的育雏数的影响
Figure PCTCN2021104283-appb-000005
注：以上结果用Mean±SEM表示；与Control组比，*P<0.05，**P<0.01
多肽组与空白组相比，秀丽线虫产生的子代总数没有显著性差异，这意味着，Ace和RV1多肽不影响秀丽隐杆线虫正常的生殖能力，说明此多肽具有良好的安全性。详见表4和图3，实验结果具有统计学意义。
实施例4
多肽对秀丽隐杆线虫的运动行为能力影响实验
1.实验材料
同实施例1。
2.实验方法
秀丽隐杆线虫同步化：同实施例1。
秀丽隐杆线虫的运动行为能力检测：同步化后L1期的幼虫，铺在已接种大肠杆菌OP50的NGM固态培养基上，分为Control组，10nM给药组，置于恒温恒湿培养箱中培养48h。然后检测以下三种运动行为能力的指标：头部摆动频率，每组挑取20只线虫至新的干净的培养基上，使其适应恢复1h后，加入适量M9缓冲液，在倒置显微镜下观察记录30s内，线虫头部从一侧摆到另一侧再摆回来的次数；身体弯曲频率，每组挑取20只线虫至新的干净的培养基上，使其适应恢复1h后，在倒置显微镜下观察记录30s内，线虫的身体弯曲次数，线虫向前爬行一个波长的距离记为一次身体弯曲；咽泵运动频率，每组挑取20只线虫至已接种大肠杆菌OP50的培养基上，使其适应恢复1h后，在倒置显微镜下放大到能够看清线虫的 咽泵运动，每只线虫录像30s，然后用PotPlayer以0.3倍速慢放录像，记数线虫的咽泵次数。对数据进行One-way ANOVAY统计分析，数据结果以Mean±SEM表示，与Control组对比，*P<0.05为显著性差异，**P<0.01为非常显著性差异。
3.实验结果
表5 多肽对秀丽隐杆线虫的运动行为能力的影响
Figure PCTCN2021104283-appb-000006
注：以上结果用Mean±SEM表示；与Control组比，*P<0.05，**P<0.01
多肽组和空白组相比，秀丽线虫的运动行为能力具有显著性差异。这意味着，Ace和RV1多肽均能够显著增强秀丽隐杆线虫的肌肉运动能力，提高线虫的运动行为能力。详见表5和图4，实验结果具有统计学意义。

Claims (7)

  1. 一种多肽，其特征在于：具有氨基酸序列XKFAA或其药学上可以接受的盐；其中X＝任意一个以上的氨基酸，或酰基，。
  2. 根据权利要求1所述的一种多肽，其特征在于：X为H-Pro-Pro-Thr-Thr-、H-Pro-Thr-Thr-、H-Thr-Thr-、T或者A。
  3. 根据权利要求1或2中所述的一种多肽，其特征在于所述多肽序列分别为，PPTTKFAA、PTTKFAA、TTKFAA、TKFAA或AKFAA。
  4. 根据权利1-3任意一项所述的多肽，其特征在于所述的多肽的每一个氨基酸为D或L型。
  5. 权利要求1-4任意一项所述的多肽在制备抗衰老的药物或保健品中的应用。
  6. 根据权利要求5所述的应用，其特征在于在多肽中还加入一种或多种药学上可接受的辅料，所述辅料包括药学领域常规的稀释剂、填充剂、粘合剂、湿润剂、吸收促进剂、表面活性剂、润滑剂和稳定剂。
  7. 根据权利要求6所述的应用，其特征在于所述的多肽制成注射液、冻干粉针剂、片剂或颗粒剂。
PCT/CN2021/104283 2020-07-27 2021-07-02 一种具有抗衰老活性的多肽及其应用 WO2022022226A1 (zh)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US17/767,403 US20240067676A1 (en) 2020-07-27 2021-07-02 Polypeptide having anti-aging activity, and application thereof
EP21849796.4A EP4190796A1 (en) 2020-07-27 2021-07-02 Polypeptide having anti-aging activity, and application thereof
AU2021314719A AU2021314719A1 (en) 2020-07-27 2021-07-02 Polypeptide having anti-aging activity, and application thereof
JP2022521564A JP2022551893A (ja) 2020-07-27 2021-07-02 抗老化活性を有するポリペプチド及びその使用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010729862.3A CN111793117B (zh) 2020-07-27 2020-07-27 一种具有抗衰老活性的多肽及其应用
CN202010729862.3 2020-07-27

Publications (1)

Publication Number Publication Date
WO2022022226A1 true WO2022022226A1 (zh) 2022-02-03

Family

ID=72827293

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/104283 WO2022022226A1 (zh) 2020-07-27 2021-07-02 一种具有抗衰老活性的多肽及其应用

Country Status (6)

Country Link
US (1) US20240067676A1 (zh)
EP (1) EP4190796A1 (zh)
JP (1) JP2022551893A (zh)
CN (1) CN111793117B (zh)
AU (1) AU2021314719A1 (zh)
WO (1) WO2022022226A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111793117B (zh) * 2020-07-27 2022-03-11 南京安吉生物科技有限公司 一种具有抗衰老活性的多肽及其应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1242043A (zh) * 1995-08-01 2000-01-19 赫尔辛基大学许可有限公司 受体配体vegf-c
US20130143757A1 (en) * 2011-12-02 2013-06-06 Board Of Regents, The University Of Texas System Methods and Compositions for Chlamydial Antigens as Reagents for Diagnosis of Tubal Factor Infertility and Chlamydial Infection
CN104402975A (zh) * 2014-12-11 2015-03-11 太原锦波生物医药科技有限公司 抗衰老短肽及其制备方法
CN109206480A (zh) * 2017-07-03 2019-01-15 大连理工大学 一类促胶原分泌超短肽及其应用
CN109232714A (zh) * 2017-07-03 2019-01-18 大连理工大学 一类用于促胶原分泌的超短肽及其应用
CN111793117A (zh) * 2020-07-27 2020-10-20 南京安吉生物科技有限公司 一种具有抗衰老活性的多肽及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018005229A1 (en) * 2016-06-30 2018-01-04 Dupont Nutrition Biosciences Aps In feed assay of microbial proteases using peptide substrates
CN109232715A (zh) * 2017-07-03 2019-01-18 大连理工大学 一类抗氧化超短肽及其应用

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1242043A (zh) * 1995-08-01 2000-01-19 赫尔辛基大学许可有限公司 受体配体vegf-c
US20130143757A1 (en) * 2011-12-02 2013-06-06 Board Of Regents, The University Of Texas System Methods and Compositions for Chlamydial Antigens as Reagents for Diagnosis of Tubal Factor Infertility and Chlamydial Infection
CN104402975A (zh) * 2014-12-11 2015-03-11 太原锦波生物医药科技有限公司 抗衰老短肽及其制备方法
CN109206480A (zh) * 2017-07-03 2019-01-15 大连理工大学 一类促胶原分泌超短肽及其应用
CN109232714A (zh) * 2017-07-03 2019-01-18 大连理工大学 一类用于促胶原分泌的超短肽及其应用
CN111793117A (zh) * 2020-07-27 2020-10-20 南京安吉生物科技有限公司 一种具有抗衰老活性的多肽及其应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BALBAA, M. ; CUNNINGHAM, A. ; HOFMANN, T.: "Secondary Substrate Binding in Aspartic Proteinases: Contributions of Subsites S"3 and S'"2 to k"c"a"t", ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, ACADEMIC PRESS, US, vol. 306, no. 2, 1 November 1993 (1993-11-01), US , pages 297 - 303, XP024753591, ISSN: 0003-9861, DOI: 10.1006/abbi.1993.1515 *
MARTINEZ, J.: "Joseph Rudinger memorial lecture: Unexpected functions of angiotensin converting enzyme, beyond its enzymatic activity", JOURNAL OF PEPTIDE SCIENCE, WILEY ONLINE LIBRARY, vol. 23, pages 741 - 748, XP055892160, DOI: 10.1002/psc.3022 *

Also Published As

Publication number Publication date
CN111793117B (zh) 2022-03-11
AU2021314719A1 (en) 2022-04-28
CN111793117A (zh) 2020-10-20
US20240067676A1 (en) 2024-02-29
EP4190796A1 (en) 2023-06-07
JP2022551893A (ja) 2022-12-14

Similar Documents

Publication Publication Date Title
Diamond Lumen dwelling protozoa: Entamoeba, trichomonads, and Giardia
Ordal et al. Pathogenic myxobacteria
JP7178333B2 (ja) ラクトバチルス・パラカゼイを含む老化遅延組成物、老化遅延組成物の製造方法、および老化遅延組成物の製造におけるラクトバチルス・パラカゼイの使用
Kohn et al. Biology and diseases of rats
JP2023166397A (ja) 酸素感受性グラム陽性細菌の保護に使用されるポリペプチド
WO2022022226A1 (zh) 一种具有抗衰老活性的多肽及其应用
WO2022022225A1 (zh) 具有抗衰老作用的多肽rv3和rv4及其应用
US20220110984A1 (en) Application of Dubosiella Newyorkensis in Prolonging Lifespan and Anti-Aging
Argüeso Human ocular mucins: The endowed guardians of sight
Kesarcodi-Watson et al. Comparative feeding and physiological energetics in diploid and triploid Sydney rock oysters (Saccostrea commercialis): II. Influences of food concentration and tissue energy distribution
JP2009058500A (ja) 血糖値を降下させる物質の評価方法、スクリーニング方法及び製造方法
Mladineo et al. In vitro culture of the zoonotic nematode Anisakis pegreffii (Nematoda, Anisakidae)
CN114522156B (zh) 一种牛磺酸的应用
Wood et al. New methods for the primary culture of gill epithelia from freshwater rainbow trout
Balls et al. Long-term amphibian organ culture
WO2021084791A1 (ja) アデノシンａ２ａ受容体を標的とする組成物
Lee et al. Promoting increased mechanical properties of tissue engineered neocartilage via the application of hyperosmolarity and 4α-phorbol 12, 13-didecanoate (4αPDD)
Strotel et al. Viability of Onchocerca volvulus in vitro
Xie et al. Effect of available food and temperature on the growth and reproduction of Daphnia rosea
CN109666066A (zh) Crtc2/Creb复合物阻断多肽及其衍生药物多肽和应用
CN114404457B (zh) 植物乳杆菌l168在制备延缓卵巢衰老的药物中的应用
Jukkola et al. New lethal disease involving type I and III collagen defect resembling geroderma osteodysplastica, De Barsy syndrome, and Ehlers-Danlos syndrome IV.
Miao et al. A comparative study on development and reproduction of the parasitoid Lysiphlebus japonicus (Hymenoptera: Aphidiidae) in symbiotic and aposymbiotic host aphids
Heslin et al. Refinement of a cell line based artificial diet for rearing the parasitoid wasp, Trichogramma pretiosum
Liu et al. Behavioral characteristics and transcriptome analysis of Mizuhopecten yessoensis in response to Neptunea arthritica cumingii predation during laboratory bottom-sowing culture

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21849796

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 17767403

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2022521564

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2021314719

Country of ref document: AU

Date of ref document: 20210702

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2021849796

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021849796

Country of ref document: EP

Effective date: 20230227